Towards a personalised clinical management of oncologic patients with acute kidney injury associated to immunecheckpoint inhibitors
Lombady partner:
- Laura Cosmai, ASST Fatebenefratelli Sacco
|
Pathology of interest: |
Acute kidney injury |
|
Area of research: |
Oncology |
|
Start date: |
01 April 2023 |
|
End date: |
31 March 2026 |
|
Funding: |
€ 102.800,00 |
|
Project partners: |
Nephrology Dept., Hospital Vall d’Hebron. Vall d´Hebron Institut de Recerca (VHIR), Barcelona, Spain
Department of Nephrology Dialysis and Internal Medicine, Medical University of Warsaw, Poland Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Italy Department of Nephrology and Hypertension, Hannover Medical School, Germany Dept. of Automatic Control, Universitat Politècnica de Catalunya (UPC), Spain Department of Public Health and Caring Sciences, Uppsala Biomedical Centre, Uppsala University, Sweden Faculty of Medicine, Bezmialem Vakif University, Turkey |
Treatment with immune checkpoint inhibitors (ICIs) has led to increased survival rates of cancer patients, who were previously untreatable, by favouring an immune response against tumour cells. ICIs action is not selective and may cause immune-related adverse events. Up to 29% of cancer patients, who receive ICIs treatment, develop acute kidney injury (AKI) secondary to ICIs use (ICI-AKI), and acute tubulointerstitial nephritis (ATIN) is the most frequent lesion. ICI-AKI is a serious complication that increases the risk of AKI recurrence after ICIs rechallenge and mortality. The diagnosis of ICI-AKI is performed by a kidney biopsy, which is highly invasive. We will collect retrospective and prospective demographic and clinical data of ICI-AKI patients as well as urine, blood and kidney tissue samples of ICI treated cancer patients during two years to identify novel biomarkers related to immune response to avoid kidney biopsy. This approach will allow personalising clinical management of these patients and improving their quality of life.